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ABSTRACT 25 
Purpose. International - predominantly American - studies undertaken in the ICUs of teaching 26 
centres show that inadequate antibiotic therapy increases mortality and stay. We sought to ascertain 27 
whether this pertains also for smaller ICUs in the Veneto region of North-east Italy. To the best of 28 
our knowledge, this is the first such survey in the Veneto or in Italy as a whole. 29 
Methods.  A retrospective, observational study was performed across five general-hospital ICUs to 30 
examine appropriateness of microbiological sampling, empirical antibiotic adequacy and outcomes.  31 
Results. Among 911 patients (mean age, 65.8 years + 16.2 SD; median ICU stay, 17.0 days [IQR, 32 
8.0-29.0]), 757 (83.1%) were given empirical antibiotics. Treatment adequacy could be fully 33 
assessed in only 212 patients (28.0%) who received empirical treatment and who had a relevant 34 
clinical sample collected at the initiation of this antibiotic (T0). Many other patients only had 35 
delayed microbiological investigation of their infections between Day 1 to Day 10 of therapy.  36 
Mortality was significantly higher among the 34.9% of patients receiving inadequate treatment 37 
(48.6% vs. 18.80%; p < 0.001). Only 32.5% of combination regimens comprised a broad-spectrum 38 
Gram-negative β-lactam plus an anti-MRSA agent, and many combinations were irrational. 39 
Conclusions. Inadequate treatment was frequent and was strongly associated with mortality; 40 
moreover, there was delayed microbiological investigation of many infections, precluding 41 
appropriate treatment modification and de-escalation. Improvements in these aspects and in 42 
antibiotic stewardship are being sought.  43 
 44 
 45 
 46 
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INTRODUCTION 49 
3 
 
Patients admitted to intensive care units (ICUs) present challenging and complex clinical problems. 50 
The estimated risk for serious infection is 5 to 10 times greater than for patients on general medical 51 
wards owing to three major factors: (1) severe underlying disease, including multiple illnesses, 52 
malnutrition, extremes of age and immunosuppression; (2) invasive medical devices, such as 53 
endotracheal tubes for mechanical ventilation and intravascular and urinary catheters, which 54 
provide entry portals for pathogens; and (3) crowding, especially in neonatal ICUs, with consequent 55 
proximity to other colonized or infected patients, increasing the risk of cross-infection [1-3]. 56 
 Antimicrobial resistance is a critical variable of ICU outcomes, co-determining patient 57 
morbidity, mortality and cost, at least in the major teaching centres where this topic has been largely 58 
investigated [4-12]. Kollef, in the U.S.A., found an infection-related mortality rate of 17.7% among 59 
486 patients receiving appropriate empirical antimicrobial therapy versus 42% among 169 receiving 60 
inappropriate antimicrobial treatment (p <0.001) [13]. The major single reason for antibiotic 61 
therapy being classed “inappropriate” was the presence of bacteria that had inherent or acquired 62 
resistance to the regimen. Others have found similar associations, particularly in bloodstream 63 
infections and sepsis [14-20],
 
with mortality shown to increase progressively for each hour’s delay 64 
in initiating adequate therapy after the onset of hypotension [21]. In the few countervailing studies, 65 
where an association between antibiotic resistance and mortality was not confirmed, few patients 66 
received microbiologically inappropriate therapy, due to early recognition of resistance and/or 67 
timely adjustment of the regimen(s) [22, 23]. Beyond its impact on mortality, initial inappropriate 68 
antibiotic therapy is also associated with extended length of stay for ICU patients [24-26]. 69 
 It is less clear whether these relationships, demonstrated in teaching centres with a complex 70 
patient mix, hold true for the smaller ICUs of district general hospitals or in the context of different 71 
countries’ cultures of prescribing and microbiological testing. We therefore present here the results 72 
of a multicentre, retrospective, observational study covering five ICUs in the Veneto region of 73 
North-east Italy, four of them in small hospitals and the fifth in a regional centre. The study had 74 
three main goals: first, to test whether, as elsewhere, there was a relationship between treatment 75 
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inadequacy and clinical outcomes; secondly, to examine the adequacy of first-line antimicrobial 76 
therapy prescribed and the principal reasons for any inadequacy; and, thirdly, to verify the 77 
appropriateness of microbiological testing performed in the participating ICUs. 78 
 79 
PATIENTS AND METHODS  80 
Study location and patients 81 
The study was conducted from 2002 to 2010 at five general hospitals in the Veneto region of North-82 
east Italy. Four hospitals were in small towns within 50 km of Vicenza and one in Vicenza itself, 83 
located between Venice and Verona. When this study was performed, the Vicenza hospital 84 
(Hospital 5) ICU had 14 beds, admitted approximately 700 patients per year, and was in a 1050-bed 85 
regional hospital; a further 5-bed high-dependency provision for post-surgical care was excluded. 86 
Hospital 1 (165 beds) admitted c. 350 patients per year to its 6-bed medical-surgical ICU; Hospital 87 
2 (400 beds) had a 10-bed general ICU admitting c. 450 patients per year; Hospital 3 (350 beds) had 88 
a 6-bed general ICU admitting c. 240 patients per year; Hospital 4 (220 beds) had a 7-bedded ICU 89 
admitting c. 340 patients per year. The total number of ICU beds represented was 43, accounting for 90 
10.8% of ICU provision in the Veneto and for 1.5% of 3739 Italy’s total intensive care bed 91 
provision as of 2005 [27]. 92 
Data Collection 93 
Patients admitted into the participating ICUs from 15 May 2002 to 10 June 2010 were assessed. 94 
Data input was performed manually in Microsoft Office Excel, with the following information 95 
recorded: hospital record number; gender; date of birth; date of hospital admission; date of ICU 96 
admission (if different); age at ICU admission, and main diagnosis at admission.  Any other 97 
diagnoses indicated in the clinical records and constituting: (1) a co-morbidity, (2) a chronic disease 98 
directly related to ICU admission, or (3) a secondary pathological event that occurred during the 99 
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ICU stay was also recorded. For statistical analysis, diagnoses were classified into main categories, 100 
all as recognised in the WHO International Statistical Classification of Diseases and Related Health 101 
Problems [28]. The date of the primary outcome (death, or transfer to another unit) was recorded. 102 
Additionally, for patients transferred from the ICU to other units in the same hospital, the dates of 103 
transfer were recorded until the final outcome (death or discharge to home).  The duration of ICU 104 
stay and entire hospital stay were calculated separately. For each antibiotic course, the regimen and 105 
dates of initiation and cessation were recorded. An antibiotic treatment was defined as empirical 106 
when it was initiated on the basis of a clinical suspicion of infection and when the causative 107 
microorganism and its antibiotic susceptibility were not yet known. Fungal infections were 108 
excluded. A sample was considered clinically relevant when it had been taken from a body site 109 
related to the reported infection. 110 
 Inadequate antimicrobial treatment was defined (based upon, e.g., [29,30) as the 111 
microbiological documentation of infection that was not being adequately treated at the time when 112 
the causative micro-organism and its antibiotic susceptibility became known, and included: (1) the 113 
absence of any agent directed against the family or genus of micro-organism present; (2) the 114 
administration of an antimicrobial agent to which the particular isolate was resistant; (3) the 115 
complete lack of antimicrobial treatment, and (4) the lack of adherence to minimum requirements in 116 
antibiotic administration (i.e., proper dosing, monitoring of drug levels when appropriate, and 117 
avoidance of unwanted drug interactions). A regimen was defined as adequate if it adequately 118 
covered all pathogens present in a sample taken at the time of clinical diagnosis (T0). Adequacy 119 
was considered not to be assessable if there was no T0 sample, if no pathogen was grown from a T0 120 
sample, or if there was no concordance between the type of specimen sent to the laboratory and the 121 
patient’s clinical presentation (e.g., clinically-diagnosed septic shock in post-surgical patients, but 122 
where the first isolates were grown from surgical wound swabs taken many days after initiation of 123 
empirical antibiotic treatment; or cases of sepsis where the only microbiological examinations 124 
performed were on bronchial aspirates). Cases where only questionable pathogens (principally 125 
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coagulase-negative staphylococci) were isolated were reviewed individually and discounted unless 126 
therapy was escalated on the basis of the microbiological result, implying that the organism was 127 
thought to be clinically significant.  128 
Statistical analyses 129 
Normally- or near-normally-distributed variables were reported as means with standard deviations 130 
and were compared by Student's t-test or by analysis of variance with the Bonferroni correction for 131 
multiple comparisons. Non-normally-distributed continuous data were reported as medians with 132 
interquartile ranges (IQRs) and were compared using the Mann-Whitney U-test or the Kruskal-133 
Wallis test. The Spearman’s rho correlation coefficient was calculated to measure the association at 134 
the ordinal level between mortality rates and their associated rates of inadequacy of first-line 135 
antimicrobial therapy. Kaplan-Meier methods were used to estimate survival rates during follow-up, 136 
whilst the log-rank test was used to test equality of survivor functions. Exploratory univariate 137 
analysis for several variables was performed to identify possible predictors of hospital mortality. 138 
Multivariable logistic regression analysis was conducted to investigate independent predictors for 139 
hospital mortality. Results of logistic regression analysis are reported as adjusted odds ratios 140 
(AORs) with 95% confidence intervals (CI). All statistical analyses were performed using STATA 141 
10.1 (StataCorp LP, College Station, TX) and a two-sided p < 0.05 was routinely considered to be 142 
significant. 143 
Ethics 144 
The study was performed in accordance with the recommendations guiding physicians in 145 
biomedical research involving human subjects adopted by the 18th World Medical Association, 146 
Helsinki, Finland, 1964 and later revisions [31]. Since it was performed retrospectively on 147 
specimens that were collected as part of the routine sampling required for the microbiological 148 
assessment of patients admitted into ICUs, there was no possible risk to any of the patients 149 
reviewed, nor any possible modification of their treatment. Consequently, individual consent was 150 
7 
 
not needed. The Institutional Sanitary Board of each hospital approved the protocol and confirmed 151 
that submission to their ethics committee was not required, provided that the principal investigator 152 
(PB) was personally responsible for the security of patient-identifiable data. 153 
 154 
RESULTS 155 
Patients 156 
The study reviewed 911 patients admitted into the five ICUs (Table 1): 570 (62.6%) were men and 157 
341 (37.4%) women. Eighty-eight (9.6%) had diabetes mellitus, 45 (5.0%) chronic renal failure, 158 
and 35 (3.9%) cirrhosis of the liver. Five hundred and fifty-two (60.6%) were admitted to an ICU 159 
with a medical diagnosis, 206 (22.6%) with a surgical diagnosis and 153 (16.8%) following major 160 
trauma. Their mean age upon ICU admission was 65.8 + 16.2 years (range, 14 - 93); those admitted 161 
to the Hospital 5 ICU were significantly younger (p <0.001) than those admitted elsewhere, partly 162 
reflecting a larger proportion of trauma patients. The median duration of ICU stay was 17.0 days 163 
(IQR, 8.0-29.0), with inter-hospitals difference approaching significance (p=0.079), while the 164 
median total length of hospital stay was 25.0 days (IQR, 14.0-44), with significant inter-centre 165 
variation (p<0.001). 166 
Antibiotic treatment 167 
A total of 3549 antimicrobial treatments were prescribed in the 5 ICUs over the study period. Of 168 
these, 3470 (97.8%) were parenteral and 79 (2.2%) oral. Seven hundred and fifty-seven patients 169 
(83.1%) received empiric antibiotic courses (1223 courses in total, 34.5% of all antimicrobial 170 
treatments) (Table 2).  Monotherapy was used in 30.2% of empirical courses, with combination 171 
therapy used in 69.8%. The commonest empirical combinations were piperacillin/tazobactam plus a 172 
glycopeptide or linezolid (52 patients, 13.4%), a carbapenem plus a glycopeptide or linezolid (47 173 
patients, 12.1%), a cephalosporin plus a glycopeptide or linezolid (27 patients, 7.0%), 174 
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piperacillin/tazobactam plus a fluoroquinolone (25 patients, 6.4%), a cephalosporin plus 175 
metronidazole (23 patients, 6.0%), and piperacillin/tazobactam plus metronidazole (21 patients, 176 
5.4%).    177 
 Combination therapies included two antibiotics in 329 cases (85.0%), three in 55 cases 178 
(14.2%), and four in three cases (0.8%).  Cephalosporins (148 courses) accounted for 40.1% of all 179 
empirical monotherapies, with cefazolin (first-generation) in 66 (44.6%), cefotetan (second-180 
generation) in four (2.7%), cefotaxime, ceftazidime, and ceftriaxone (third-generation) in 69 181 
(46.6%), and cefepime (fourth-generation) in nine (6.1%). Other frequently-prescribed 182 
monotherapies were piperacillin/tazobactam (74 courses, 20% of all monotherapies) and other 183 
penicillin/β-lactamase inhibitor combinations (68 courses, 18.4%).      184 
 Only 126 of the 388 combination regimens (32.5%) comprised a broad-spectrum Gram- 185 
negative β-lactam plus an anti-MRSA agent (a glycopeptide, usually teicoplanin, or linezolid); 91 186 
(12.2%) of the first-line empirical regimens were irrational or redundant poly-pharmacy, commonly 187 
comprising a combination of a β-lactam with anti-anaerobe activity (i.e. a β-lactamase inhibitor 188 
combination or a carbapenem) with metronidazole.  189 
 The median duration of the first-line empirical therapy was 11.0 days (IQR, 6.7 – 19.0) for 190 
patients with bacteraemia, 9.0 days (5.0 – 14.0) for medical patients and 10.0 days (7.0 – 17.0) for 191 
surgical patients. Although there is a growing trend to shorten treatment durations, particularly in 192 
Northern Europe, these longer courses are typical of Italy in the study period and are not out of line 193 
with many international guidelines [32]. 194 
Laboratory data  195 
There was often a poor match between the site of infection indicated in the patient record and the 196 
specimens from which organisms, if any, were grown by the laboratory.  Moreover, there were 197 
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frequent long delays between the clinical diagnosis and any result becoming available to the treating 198 
clinician(s).  199 
 At the four smaller sites (Hospitals 1-4), respiratory samples accounted for >50% of all 200 
specimens with a pathogen grown, and for fully 74% and 82% at Hospitals 2 and 3, respectively 201 
(Figure 1). Blood and (especially) urine were rarely sampled, even when an infection was believed 202 
to involve these sites. Thus, at Hospitals 2 and 3, urines accounted for only 5.6% and 8.7% of total 203 
microbiological investigations, respectively. These patterns seem to reflect a practice of performing 204 
surveillance cultures of respiratory secretions and basing therapy upon these, rather than of 205 
undertaking microbiological investigations of actual infections.  206 
Clinical specimens yielding an organism were collected at the initiation of empirical 207 
antibiotic (T0) only from 251 of the 911 patients (27.6%). Sixteen of these 251 did not receive 208 
antibiotics, as they were considered to be colonised rather than infected (n=13) or died early (n=3), 209 
leaving 235 patients who had a T0 specimen and an assessable empirical antibiotic treatment.  This 210 
total reduced to 212 after exclusion of 23 patients whose T0 sample was from a body site different 211 
to the infection recorded in the patient's notes. Samples yielding reported organisms were taken 212 
within 10 days of therapy initiation from a further 361 patients (39.6%) whilst, in the remaining 299 213 
cases (32.8%), the interval between initiation of antibiotic therapy and the first sample with a 214 
reported organism was >10 days, or there was no relationship between the type of specimen from 215 
which any organism was grown and the patient’s clinical setting (Table 3). The median interval 216 
between the initiation of empirical antibiotic therapy and the availability of a first (post-infection) 217 
antibiotic sensitivity result was 7 days (IQR, 3.0-14.0), with significant variation amongst the five 218 
sites (p < 0.001).  The lag between arrival of a growth-yielding sample at the laboratory and the 219 
availability of the result varied between sites from 3 to 4.5 days, meaning that around half of this 220 
overall 7-day delay was between the clinical diagnosis of infection and the specimen being sent to 221 
the laboratory for microbiology.  It follows that many of the patients were already receiving 222 
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antibiotics at the time the first culture was taken, potentially compromising pathogen recovery and 223 
meaning that many were nearing the end of their antibiotic course when any microbiological results 224 
became available.  225 
The lack of a T0 organism may be because no specimen was sent to the laboratory, or 226 
because no organism was grown by the laboratory.  Discriminating these scenarios in the hospital 227 
record systems proved difficult but, for a random sample of 23 patients lacking culture results, we 228 
could identify six who had a relevant-site T0 sample from which the laboratory failed to grow a 229 
pathogen, eight who had only a T1 to T10 specimen failing to yield growth, and nine who had no 230 
evidence of any specimen being sent to the microbiology laboratory within 10 days of clinical 231 
diagnosis. 232 
In total, 313 isolates from clinical samples (regardless of site and apparent relevance) were 233 
collected at T0 from the 235 patients starting empirical treatment. In 147 cases (62.6%) the 234 
organism(s) proved susceptible to the antibiotic regimen initiated whereas 88 (37.4%) patients had 235 
bacteria resistant to the regimen initiated. The lowest proportion of resistance was at Hospital 1 236 
(25.0%) and the highest at Hospital 2 (42.4%). Resistance to the empirical therapy was more 237 
prevalent (192/347, 53%, p <0.001) amongst cases who had initial isolates collected in the T1-10 238 
period, again with the lowest proportion (49.1%) at Hospital 4 and the highest (61.5%) at Hospital 239 
2. The differential in resistance, between patients with a T0 vs. T1-10 initial sample was moderately 240 
significant even in the bacteraemia subset, where 35/54 (64.8%) isolates from patients with a T1-10 241 
sample were resistant to the empirical therapy given vs. 14/34 (41.2%) (p = 0.098) isolates from T0 242 
samples, whilst the difference in resistance between the whole series bacteraemic vs. non bacteraemic  243 
patients was not significant (p=0.1891) (Table 4). Among the 212 patients who had clinically relevant 244 
T0 samples, resistance to the empirical therapy given was observed in 74 (34.9%), with the lowest 245 
proportion (22.6%) at Hospital 1 and the highest (40.6%) at Hospital 2 (p = 0.2277). A greater 246 
proportion of resistance to empirical therapy (142/266, 53.4%, was seen in cases with an initial T1-247 
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10 sample, with the lowest rate (43.4%) at Hospital 4 and the highest (70.0%), again, at Hospital 2 248 
(p=0.01). Amongst bacteraemic cases, 6/24 (25.0%) of T0 isolates were resistant compared with 249 
13/25 (52%) among those collected from T1-10.  There was little obvious demographic difference 250 
between the groups with a first relevant-site sample at T0, T1-10 and T>10 (or no relevant sample 251 
at all), with average ages of 66.3, 65.8, and 66.5 years and medical:surgical:trauma ratios of 252 
73.5:15.5:11.0; 59.0:19.9:21.1 and 71.2:14.8:14.0, respectively.  253 
 The frequent lateness of microbiological data may explain the small proportion of cases (282 254 
out of 757, 37.2%) in whom empirical regimens were adjusted based upon susceptibility results. 255 
The vast majority of these changes (252/282, 89.4%) were escalations, meaning the addition of 256 
further agents or switches to broader-spectrum agents; first-line empirical antibiotic was stepped-257 
down in only 30 cases (10.6%).  258 
Outcomes 259 
Two hundred and twenty-seven patients (24.9%) died during their ICU stay and 316 (34.7%) during 260 
their entire hospitalization. One hundred and forty-three of the ICU deaths (63% of all ICU deaths) 261 
could reasonably be related to infection. 262 
 Patient primary outcome data in relation to treatment adequacy for the 212 cases with a 263 
relevant-site T0 clinical specimen is displayed in Table 5.   Among the 74 (34.9%) whose empirical 264 
antibiotic(s) failed to cover the organisms subsequently identified there were 36 ICU deaths 265 
(48.6%) vs. 26 deaths (18.8%) among the 138 receiving therapy that covered all pathogens present 266 
(p <0.001).  This pattern was maintained among patients whose first relevant specimen was taken in 267 
the T1-10 interval, where there was 43% mortality among those receiving inadequate therapy vs. 268 
23% among those receiving adequate antimicrobial therapy (OR = 1.84; 95% CI, 1.3 to 2.5).   In 269 
this case, however, it is impossible to distinguish whether inadequacy was against the initial 270 
pathogen, its resistant progeny, or against a secondary invader.    Overall mortality rates among 271 
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patient with a first relevant-site sample at T0, T1-10 and T>10 (or no relevant sample at all were 272 
29.2%, 19.9 % and 27.6%, respectively.  273 
 The adequacy of the initial regimen did not significantly affect the duration of ICU stay (p = 274 
0.93) (Figure 2) partly because survivors who were hospitalized for extended periods were balanced 275 
by cases who died early. 276 
 Development of septic shock was a significant predictor of mortality as was the patient’s age 277 
(p <0.001). Non-survivors also were more likely to have had acute renal failure upon admission (p 278 
< 0.001). By contrast, those admitted because of traumatic shock were more likely to survive (p < 279 
0.001), perhaps owing to a higher probability of receiving adequate antibiotic treatment, given to 280 
36.6% of trauma patients vs. 30.9% of other patient categories.  281 
 The commonest pathogens isolated from bloodstream samples and their associated rates of 282 
inadequate antimicrobial treatment were P. aeruginosa (n = 23; 80% inadequacy), MRSA (n = 19; 283 
80% inadequacy), and E. coli (n = 14; 77% inadequacy). The large number of MRSA is 284 
unsurprising: EARS-net data (http://www.ecdc.europa.eu) show that the MRSA rate among 285 
bloodstream S. aureus fluctuated between 33.2 and 39.4% through the study period.  286 
Despite extensive cephalosporin use (above) only two cases of Clostridium difficile 287 
diarrhoea were recorded, though it should be cautioned that diarrhoeal patients were not routinely 288 
screened for this pathogen in the study period, leading to likely under-recording.    289 
 290 
DISCUSSION 291 
Studies of antibiotic inadequacy and its consequences in severely-ill patients have largely been 292 
undertaken in teaching centres [13-21, 33-35], particularly in the U.S.A. [13,15,17,33]. We 293 
investigated whether their general conclusion - that inadequate empirical therapy is associated with 294 
increased mortality – applied also for smaller centres in the Veneto. 295 
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 Assessing treatment adequacy proved challenging, owing to the many patients in whom 296 
microbiology was carried out improperly or belatedly. Clinical specimens were collected at 297 
initiation of empirical antibiotics (T0) for only 31.0% (235/757) of patients starting an initial 298 
empirical antibiotic course, and only 28% (212) had a sample taken from the reported infection site. 299 
In rather more cases (347, 45.8%), initial samples were taken between T1-10 whilst, for 299 cases 300 
(39.5%), the interval to the first sample was >10 days, or there was no concordance between any 301 
laboratory specimen and the patient’s clinical setting.  Resistance to the initial antibiotic therapy 302 
was significantly more prevalent amongst T1-10 isolates than among those collected at T0, 303 
regardless of whether comparison was irrespective of body site (55.3 vs. 37.4%) or solely from 304 
isolates from the relevant site (53.4 vs. 34.9%). Similar patterns – with greater resistance in T1-10 vs. T0 305 
samples - were seen for the subset of bacteraemia patients (64.1% vs. 41.1% for isolates from any body 306 
site and 52.0 vs. 25.0% amongst bloodstream isolates). Greater resistance rates among ‘late’ isolates 307 
may reflect selection of resistance in the original pathogen, or super-infection by more resistant 308 
organisms during therapy. 309 
  When only the 212 empirically treated patients with a relevant T0 sample were analysed 310 
(Table 5), 138 (65.1%) treatments were assessed as adequate, with 18.8% deaths in the ICU, versus 311 
74 (34.9%) judged inadequate, with 48.6% deaths) (p=<0.001).    Total mortality among these 212 312 
patients with timely microbiological investigation was 29.2% compared with 27.6% among the 313 
patients who had very belated microbiological investigation (>10 days) or no investigation at all.  314 
These two groups were well matched in terms of average age and proportions of medical vs. 315 
surgical vs. trauma cases; the overall similarity in outcome may well reflect the fact that, even 316 
where microbiological investigation was performed, therapy was rarely changed.  Mortality was 317 
lower (19.9%) among the patients who had a first relevant sample in the T0-10 period, but this 318 
group contained a higher proportion of trauma patients, who anyway tended to have better 319 
outcomes. 320 
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This study, covering five small ICUs in the Veneto, thus confirms a significant association 321 
between inadequate empirical antimicrobials and ICU mortality. S. aureus and resistant gram-322 
negative bacteria were the pathogens most frequently associated with poor outcomes, also as seen 323 
elsewhere [14,15,17,21,33-35]. Furthermore, and in keeping with a recent meta-analysis [36], ICU 324 
infections following trauma had lower mortality, perhaps because most trauma patients are younger 325 
and have fewer co-morbidities. In contrast to several published studies [8,14,18,20,24-26], we 326 
found no relationship between treatment adequacy and duration of ICU stay, though this calculation 327 
may be confounded by how duration is counted for patients who die early.    328 
 The frequent lack of prompt microbiological investigation is the core finding of this study. 329 
In many cases clinicians’ undertook seemed to depend upon surveillance sampling for bacterial 330 
colonization of the lower airways rather than direct microbiological investigation of the clinically-331 
diagnosed infections, often with an excess of antibiotics.  Such overtreatment seems widespread in 332 
Italy [37,38] and elsewhere [38,40].  333 
 Even when relevant specimens were collected, they often were collected late, meaning that 334 
the organisms grown may have been secondary colonists, and that susceptibility results only 335 
became available around the time when primary empirical treatment was ending, or even 336 
afterwards. This may explain the infrequency of treatment de-escalation based on laboratory results. 337 
Even Hospital 5 - where laboratory results were available earlier - was little exception and, in all but 338 
two cases, changes to initial empirical antibiotic treatment were escalations, not de-escalations.  339 
 In summary, despite its limitations (e.g., being retrospective, exclusion of fungal infections, 340 
and the difficulty of evaluating empirical therapy among patients whose microbiological 341 
investigation was inadequate), this study provided a clear picture of sub-optimal microbiological 342 
testing and antibiotic use in the five ICUs. There was frequent antibiotic misuse, inappropriate 343 
empirical treatment, and high variability in (generally overlong) treatment duration and a 344 
considerable need for the ICUs to improve specimen-taking and use of the microbiology laboratory.  345 
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Notably, the ICUs lacked local antibiotic practice guidelines, which represent one tool for clinicians 346 
to manage patient and stewardship needs. Clinicians should be aware that any transient clinical 347 
benefit achieved by overtreatment is counterbalanced by collateral damage and detriment to the 348 
community as a whole via increased selection pressure for resistance. These issues are becoming 349 
even more serious and urgent with the recent and extensive dissemination in Italy of Klebsiella 350 
pneumoniae with KPC carbapenemases [20,41,42]. Poorly directed antibiotic use may have helped 351 
to drive this dissemination, which saw the proportion of carbapenem-resistant bloodstream K. 352 
pneumoniae in Italy rise from 1-2% from 2006-9 to over 30% in 2013-14 353 
(http://www.ecdc.europa.eu). Most of these isolates are, however, clonal [43] and it therefore seems 354 
likely that infection control failures are a greater issue, a view supported by the observation that 355 
near-identical strains of carbapenemase-producing K. pneumoniae were reduced in prevalence in 356 
Israel by improved infection control rather than stewardship changes.  Carbapenemase-producing 357 
K. pneumoniae remain rare at the ICUs included here (5-8 isolates, hospital-wide, per annum from 358 
2010-12 in Hospital 5, rising to 14 in 2013, 18 in 2014 and 34 in the first half of 2015) but are 359 
hugely more prevalent in a major teaching centre just 60 km away (data not shown). 360 
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Table 1   Characteristics of the study patients 
Site Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5 Total p-value § 
N° of pts. 184 172 136 171 248 911  
N° (%) of male patients 119 (64.7) 107 (62.2) 89 (65.4) 102 (59.7) 153 (61.7) 570 (62.6) 0.819 
N° (%) of female patients 65 (35.3) 65 (37.8) 47 (34.6) 69 (40.3) 95 (38.3) 341 (37.4) 0.819 
Mean age (years) + SD 69.4 + 14.5 69.3 + 14.7 65.3 + 15.9 69.0 + 14.6 58.7 + 17.4 65.8 +  16.2 < 0.001 *** 
Age range (years) 18 - 92 20 - 93 17 - 91 16 - 91 14 - 89 14 - 93  
Median length of ICU stay (days) (IQR) 15.0 (7.7-25.0) 19.0 (9.0-33.5) 18.0 (10.0-30.0) 20.0 (7.0-33.0) 16.0 (9.0-24.0) 17.0 (8.0-29.0) 0.079 * 
Median length of hospital stay (IQR) 19.0 (11.5–32.5) 35.0 (18.5–56.0) 25.0 (14.0–44.0) 31.5 (16.0-50.0) 22.0 (12.0–37.5) 25.0 (14.0–44.0) < 0.001 *** 
N° (%) of ICU deaths 40 (21.7) 50 (29.0) 33 (24.3) 37 (21.7) 67 (27.0) 227 (24.9) 0.383 
N° (%) of hospital deaths 54 (29.3) 70 (40.7) 43 (31.6) 55 (32.2) 94 (37.9) 316 (34.7) 0.1239 
Diagnosis on admission:        
       Medical (%) 129 (70.1) 103 (59.9) 79 (58.1) 104 (60.9) 151 (60.9) 552 (60.6) < 0.001 *** 
       Surgical (%) 41 (22.3) 35 (20.3) 31 (22.8) 49 (28.6) 36 (14.5) 206 (22.6) < 0.001 *** 
       Trauma (%) 14 (7.6) 34 (19.8) 26 (19.1) 18 (10.5) 61 (24.6) 153 (16.8) < 0.001 *** 
Patients admitted from:        
       The community (%) 82 (44.6) 71 (41.3) 70 (51.5) 68 (39.8) 100 (40.3) 391 (42.9) < 0.001 *** 
       Another hospital (%) 32 (17.4) 17 (9.9) 18 (13.2) 19 (11.1) 44 (17.7) 130 (14.3) < 0.001 *** 
       Other wards (%) 70 (38.0) 84 (48.8) 48 (35.3) 84 (49.1) 104 (42.0) 390 (42.8) < 0.001 *** 
Patients discharged home (%) 5 (2.7) 3 (1.7) 2 (1.5) 5 (2.9) 1 (0.4) 16 (1.8) 0.284 
Patients transferred to other wards (%) 78 (42.4) 105 (61.0) 62 (45.6) 99 (57.9) 100 (40.3) 444 (48.7) < 0.001 *** 
Patients transferred to other hospital (%) 61 (33.2) 14 (8.1) 39 (28.7) 30 (17.5) 80 (32.3) 224 (24.6) < 0.001 *** 
Diabetes (%) 16 (8.7) 22 (12.8) 13 (9.6) 23 (13.5) 14 (5.7) 88 (9.6) 0.04923 ** 
Chronic renal failure (%) 9 (4.9) 12 (7.0) 6 (4.4) 9 (5.3) 9 (3.6) 45 (5.0) 0.636 
Cirrhosis (%) 5 (2.7) 12 (7.0) 7 (5.2) 7 (4.1) 4 (1.6) 35 (3.9) 0.056 * 
Sepsis/septic shock (%) 22 (12.0) 34 (19.8) 22 (16.2) 37 (21.7) 42 (17.0) 157 (17.3) 0.146 
§ *** p<0.01; ** p<0.05; * p<0.1 
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Table 2 Initial empiric antibiotic therapy receidev by patients surveyed 
Antibiotics N° pts. 
receiving 
antibiotic, N° 
(%) * 
Proportion of 
total antibiotic 
use, % ç 
Proportion of 
mono-
therapy,% § 
Proportion of 
combination 
therapy, % ^ 
Cephalosporins 253 (33.4) 20.7 40.1 12.3 
Cefazolin 85 (11.2) 7.0 17.8 2.3 
Ceftriaxone 71 (9.4) 5.8 10.1 4.0 
Cefotaxime 37 (4.9) 3.0 6.5 1.5 
Ceftazidime 26 (3.4) 2.1 2.2 2.1 
Cefepime 24 (3.1) 2.0 2.4 1.8 
Cefotetan 8 (1.1) 0.7 1.1 0.4 
Ceftizoxime 2 (0.3) 0.1 0.0 0.2 
Piperacillin/tazobactam 217 (28.6) 17.7 20.5 16.8 
Glycopeptides 147 (19.4) 12.0 3.2 15.3 
Teicoplanin 107 (14.1) 8.7 2.4 11.7 
Vancomycin 40 (5.3) 3.3 0.8 3.6 
Fluoroquinolones 133 (17.5) 10.9 8.9 11.8 
Levofloxacin 79 (10.4) 6.5 4.3 7.5 
Ciprofloxacin 53 (7.0) 4.3 4.6 4.3 
Moxifloxacin 1 (0.1) 0.1 0.0 0.0 
Carbapenems 120 (15.8) 9.8 6.2 11.6 
Meropenem 77 (10.2) 6.3 2.7 8.0 
Imipenem 43 (5.7) 3.5 3.5 3.6 
Penicillins 102 (13.5) 8.3 19.4 3.5 
Amoxicillin/clavulanate 52 (6.9) 4.3 10.5 1.5 
Ampicillin/sulbactam 40 (5.3) 3.3 7.8 1.3 
Oxacillin 5 (0.7) 0.4 0.5 0.4 
Penicillin 2 (0.3) 0.2 0.3 0.1 
Piperacillin 2 (0.3) 0.2 0.3 0.1 
Ampicillin 1 (0.1) 0.1 0.0 0.1 
Metronidazole 99 (13.1) 8.1 0.0 11.8 
Aminoglycosides 53 (7.0)  4.3 0.0 6.3 
Amikacin 21 (2.8) 1.7 0.0 2.5 
Gentamicin 17 (2.2) 1.4 0.0 2.0 
Netilmicin 8 (1.1) 0.7 0.0 1.0 
Tobramicin 7 (0.9) 0.6 0.0 0.8 
Clindamycin 48 (6.3) 3.9 0.8 5.4 
Others 47 (6.2) 3.8 1.0 5.2 
TOTALS  100.0 100.0 100.0 
* Many patients received more than one antibiotic, meaning that this column does not total 100%. Antibiotic 
classes received by > 5% of patients are shown; other antibiotics used in a few cases included macrolides, 
linezolid, chloramphenicol, and tigecycline. 
ç Proportion of total 1223 antibiotic courses administered as initial empiric therapy 
§ Proportion of monotherapy was calculated as the N° of patients receiving the antibiotic alone, as a proportion of 
all 369 patients receiving monotherapy 
^ Proportion of combination therapy was calculated as the N° of patients receiving the individual antibiotic as a 
component of their combination therapy, as a proportion of the 388 patients receiving combination therapy 
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Table 3 Timing of initial clinical specimens*  
 
TIME OF SAMPLING  Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5 Total (%) 
   T0 (same day as clinical diagnosis)  34 33 43 52 89 251 (27.6) 
        Cases with bacteraemia 2 4 2 12 22 42  
        Non-bacteraemic cases 32 29 41 40 67  209  
Cases with a relevant-site specimen 31 32 36 43 70 212 
  T1 (within 10 days of clinical diagnosis) 86 65 30 69 111 361 (39.6) 
        Cases with bacteraemia 9 8 0 10 42 69  
      Non-bacteraemic cases 77 57 30 59 69 292  
Cases with a relevant-site specimen 67 50 28 53 68 266 
  Day > 10 (>10 days after clinical diagnosis, or no sample 64 74 63 50 48 299 (32.8) 
        Cases with bacteraemia 3 9 4 6 15 37 
      Non-bacteraemic cases 61 65 59 44 33 262  
 TOTAL 184 172 136 171 248 911 (100.0) 
 
* including patients not given any antimicrobial therapy 
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 Table 4 Bacterial resistance (R) or susceptibility (S) to empirical therapy administered * 
 Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5 Total (%) 
CASES WITH ANY 
MICROBIOLOGICAL SAMPLE  
R S R S R S R S R S R S 
Empirically-treated patients with any T0 
sample (n=235) 
8  
(25.0) 
24  
(75.0) 
14 
(42.4) 
19 
(57.6) 
11 
(29.7) 
26 
(70.3) 
19 
(37.2) 
32 
(62.8) 
36 
(43.9) 
46 
(56.1) 
88  
(37.4) 
147  
(62.6) 
Cases with bacteraemia (n=34) 0 1 2 2 1 1 4 8 7 8 14 20 
Non-bacteraemic cases (n=201)  8 23 12 17 10 25 15 24 29 38 74 127 
Total treatments 32 33 37 51 82 235 
Total isolates from  T0 samples 35 40 54 63 121 313 
Empirically-treated patients with any day 
T1-10 sample (n=347) 
46 
(55.4) 
37  
(44.6) 
40 
(61.5) 
25 
(38.5) 
15 
(53.6) 
13 
(46.4) 
30 
(49.1) 
31 
(50.9) 
61 
(55.5) 
49 
(44.5) 
192 
(55.3) 
155 
 (44.7) 
Cases with bacteraemia (n=54) 6 3 5 3 0 0 6 4 18 9 35 19 
Non-bacteraemic cases (n=293) 40 34 35 22 15 13 24 27 43 40 157 136 
Total treatments 83 65 28 61 110 347  
Total isolates from T1-10 samples 112 86 45 85 221 549 
CASES WITH A RELEVANT-SITE ^ 
CLINICAL SPECIMEN  
R S R S R S R S R S R S 
Empirically-treated patients  with a 
relevant-site T0 sample (n=212) 
7  
(22.6) 
24  
(77.4) 
13  
(40.6) 
19  
(59.4) 
10  
(27.8) 
26  
(72.2) 
16  
(37.2) 
27 
(62.8) 
28 
(40.0) 
42 
 (60.0) 
74 
 (34.9) 
138 
(65.1) 
Cases with bacteraemia (n=24) § 0 1 1 2 1 1 2 6 2 8 6 18 
Non-bacteraemic cases (n=188)  7 23 12 17 9 25 14 21 26 34 68 120 
Total treatments 31 32 36 43 70 212 
Empirically-treated patients  with a 
relevant-site T1-10 sample (n=266) 
35  
(52.2) 
32 
 (47.8) 
35  
(70.0) 
15  
(30.0) 
15  
(53.6) 
13  
(46.4) 
23 
 (43.4) 
30 
 (56.6) 
34 
 (50.0) 
34  
(50.0) 
142  
(53.4) 
124  
(46.6) 
Cases with bacteraemia (n=25) 2 2 5 1 0 0 2 4 4 5 13 12 
Non-bacteraemic cases (n=241) 33 30 30 14 15 13 21 26 30 29 129 112 
Total treatments 67 50 28 53 68 266 
Total patients 184 172 136 171 248 911  
* Defined as in Methods, p.5-6 
^  i.e., taken from a body site corresponding to an infection recorded in the clinical records 
§ Excluding coagulase-negative staphylococci which, based upon the clinical records, were not considered to be clinically significant  
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Table 5 Patient primary outcome* in relation to treatment adequacy among patients with a baseline relevant 
specimen 
 
 
 
 
 
 
 
* Defined as in Methods, p. 5-6 
 
 
 TOTAL 
TREATED 
(WITH 
RELEVANT 
SPECIMEN) 
TOTAL 
ADEQUATE  
(% of total 
treated) 
DEATH  
(% of 
adequately 
treated) 
SURVIVAL  
(% of 
adequately 
treated) 
TOTAL 
INADEQUATE  
(% of total 
treated) 
DEATH  
(% of 
inadequately 
treated) 
SURVIVAL  
(% of 
inadequately 
treated) 
Hospital 1 31 24 (77.4) 5 (20.8) 19 (79.2) 7 (22.6) 5 (71.4) 2 (28.6) 
Hospital 2 32 19 (59.4) 4 (21.0) 15 (79.0)  13 (40.6) 8 (61.5) 5 (38.5) 
Hospital 3 36 26 (72.2) 5 (19.2) 21 (80.8) 10 (27.8) 2 (20.0) 8 (80.0)  
Hospital 4 43 27 (62.8) 3 (11.1) 24 (88.9) 16 (37.2) 6 (37.5) 10 (62.5) 
Hospital 5 70 42 (60.0) 9 (21.4) 33 (78.6) 28 (40.0) 15 (53.6) 13 (46.4) 
TOTAL 212 (100.0) 138 (65.1) 26 (18.8) 112 (81.2) 74 (34.9) 36 (48.6) 38 (51.4) 
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Figure captions 
 
Figure. 1 Sites of clinically-diagnosed infections (grey) compared to number of specimens sampled 
(black), by site.  Numbers indicate hospitals.   
Figure 2  Duration of ICU stay in relation to adequacy of empirical treatment 
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